RESUMO
BACKGROUND: Adenomyosis is one of the structural causes of abnormal uterine bleeding, which often presents as heavy menstrual bleeding. Mostly because of the poor understanding of its pathophysiology, medical management of adenomyosis-induced heavy menstrual bleeding is still a challenge. We have previously reported that glycolysis is crucial to endometrial repair following menstruation and that suppressed glycolysis can cause heavy menstrual bleeding. OBJECTIVE: This study aimed to test the hypothesis that meclizine, a drug with an excellent safety profile, alleviates heavy menstrual bleeding in mice with induced adenomyosis using a simulated menstruation model. STUDY DESIGN: Adenomyosis was induced in 36 female C57BL/6 mice using endometrial-myometrial interface disruption. Three months after induction, the mice were randomly divided into the following 3 groups: low-dose meclizine, high-dose meclizine, and controls. Treatment with meclizine or vehicle started shortly before the simulated menstruation procedure and ended before progesterone withdrawal. The amount of blood loss was quantified and uterine tissue was harvested for histologic evaluation of the grade of endometrial repair. We performed immunohistochemistry analysis of 4 proteins critically involved in glycolysis: Glut1 (glucose transporter 1), Hk2 (hexokinase 2), Pfkfb3 (6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3), and Pkm2 (pyruvate kinase M2). The extent of tissue fibrosis in both ectopic and eutopic endometria was evaluated using Masson trichrome staining. RESULTS: In mice with induced adenomyosis, meclizine accelerated endometrial repair in a dose-dependent manner and reduced the amount of menstrual bleeding. Meclizine administration raised endometrial immunoexpression of Hk2 and Pfkfb3 but not of Glut1 or Pkm2. The extent of endometrial fibrosis was reduced following the meclizine administration. Remarkably, these favorable changes were accompanied by the suppression of lesional progression, as evidenced by the dose-dependent reduction in the extent of fibrosis (a surrogate for lesional progression). CONCLUSION: These encouraging results, taken together, suggest that glycolysis may be a promising therapeutic target and that meclizine may hold therapeutic potential as a nonhormonal treatment for adenomyosis-induced heavy menstrual bleeding without exacerbating the disease.
Assuntos
Adenomiose , Modelos Animais de Doenças , Endométrio , Glicólise , Meclizina , Camundongos Endogâmicos C57BL , Animais , Feminino , Endométrio/efeitos dos fármacos , Endométrio/metabolismo , Endométrio/patologia , Adenomiose/tratamento farmacológico , Adenomiose/complicações , Camundongos , Meclizina/uso terapêutico , Meclizina/farmacologia , Glicólise/efeitos dos fármacos , Menorragia/tratamento farmacológico , Menorragia/etiologia , Piruvato Quinase/metabolismo , Transportador de Glucose Tipo 1/metabolismoAssuntos
Humanos , Feminino , Gravidez , Êmese Gravídica , Hiperêmese Gravídica/diagnóstico , Hiperêmese Gravídica/etiologia , Hiperêmese Gravídica/tratamento farmacológico , Prometazina/uso terapêutico , Clorpromazina/uso terapêutico , Ondansetron/uso terapêutico , Dimenidrinato/uso terapêutico , Antagonistas dos Receptores Histamínicos/uso terapêutico , Meclizina/uso terapêutico , Metoclopramida/uso terapêuticoRESUMO
Se realiza el estudio de las historias clínicas de 185 niños atendidos en la consulta de cefalea del Hospital Docente del Cerro, desde abril de 1988 hasta abril de 1993. Se agruparon los hallazgos clínicos en antecedentes patológicos familiares y personales, características de la cefalea, resultados de la exploración física, investigaciones realizadas y tratamiento recibido. El grupo más afectado fue el de más de 9 años, con predominio del sexo masculino. La variedad de cefalea más frecuente fue la migraña sin aura. En las características del dolor predominaron la localización bifrontal, pulsátil, severo, de 2 ó 3 horas de duración, 2 ó 3 veces a la semana. El tratamiento medicamentoso más utilizado fué meclizine